Innovating.works Conecta tu I+D

Mostrando 1 al 20 de 49 resultados

Thera4Care: THERANOSTICS ECOSYSTEM FOR PERSONALISED CARE Thera4Care represents a large unique consortium, gathering well-established European academic radiotheranostic centres, strong industry part...
2024-09-13 - 2029-09-30 | Financiado

ILLUMINATE: INCREASING LUTETIUM PRODUCTION WHILE LEVERAGING METABOLIC IMAGING TO ENHANCE THERANOSTICS EFFECTIVE... Selective targeting of therapy with antibody-radioisotope combinations have led to major advances in treating cancers that are resistant to...
2024-09-02 - 2029-03-31 | Financiado

SECRET: Exploring the therapeutic potential of perinatal cell SECRETomes Over the past two decades, cells isolated from human perinatal (or birth-associated) tissues (amniotic membrane, umbilical cord tissue and c...
2024-07-16 - 2028-08-31 | Financiado

MENTOR: Metabolic control of cell growth by mTOR in health and disease a multi disciplinary training MENTOR is a multi-disciplinary training network which focuses on the mTOR pathway, a central mechanistic hub that integrates nutritional cue...
2024-07-09 - 2028-12-31 | Financiado

e-QuoL: e health tools to promote Equality in Quality of Life for childhood to young adulthood cancer patien... UNIVERSITAETSKLINIKUM ESSEN participó en un HORIZON EUROPE: HORIZON-MISS-2023-CANCER-01 Cancer affects 35,000 children, adolescents and young adults (CAYAC) in Europe each year. Current 5-year survival rates are 80%, but the int...
2023-12-13 - 2027-12-31 | Financiado

METATARGET: Targeting the Metabolic Dependencies of Metastatic Tumor Cells UNIVERSITAETSKLINIKUM ESSEN tramitó un HORIZON EUROPE: ERC-2022-STG Metastasis is responsible for over 90% of deaths that occur in patients with cancer. So far there are no therapies that precisely target a m...
2023-11-28 - 2029-05-31 | Financiado

BIOSMALL: Identification of subtype-specific biomarkers in small cell lung cancer UNIVERSITAETSKLINIKUM ESSEN participó en un HORIZON EUROPE: HORIZON-MSCA-2022-SE-01 Although small cell lung cancer (SCLC) is a particularly aggressive disease, targeted therapies have remained largely unsuccessful and there...
2023-08-02 - 2027-09-30 | Financiado

BEYOND STRESS: The stress granule machinery controls metabolic signalling through mTOR at steady-state UNIVERSITAETSKLINIKUM ESSEN tramitó un HORIZON EUROPE: ERC-2021-ADG MTOR kinase is an oncogenic master regulator of metabolism and cell growth and is known to reside in two multiprotein complexes. Upon stress...
2022-05-31 - 2028-04-30 | Financiado

MITI: Non-ionizing Metabolic Imaging for predicting the effect of and guiding Therapeutic Interventions UNIVERSITAETSKLINIKUM ESSEN participó en un HORIZON EUROPE: HORIZON-EIC-2021-TRANSITIONOPEN-01 MITI will develop and mature a novel, ground-breaking technology for high precision non-ionizing metabolic imaging, enabling fast and non-in...
2022-03-02 - 2024-09-30 | Financiado

CEN: Cerebellum and Emotional Networks UNIVERSITAETSKLINIKUM ESSEN participó en un H2020: H2020-MSCA-ITN-2020 This Innovative Training Network (ITN) brings together leading European research labs for the interdisciplinary study of cerebellar contribu...
2021-04-30 - 2025-05-31 | Financiado

FORTEe: Get strong to fight childhood cancer an exercise intervention for children and adolescents undergoi... UNIVERSITAETSKLINIKUM ESSEN participó en un H2020: H2020-SC1-BHC-2018-2020 Cancer is the first leading cause of death by non-communicable diseases in children in Europe. During cancer treatment, patients’ morbidity...
2021-02-03 - 2026-08-31 | Financiado

RETENTION: heaRt failurE paTient managEment and iNTerventIOns usiNg continuous patient monitoring outside hospi... UNIVERSITAETSKLINIKUM ESSEN participó en un H2020: H2020-SC1-BHC-2018-2020 Heart failure (HF) is a prominent chronic disease, despite efforts in improving its prevention, diagnosis and treatment, represents the lead...
2021-01-22 - 2025-04-30 | Financiado

MAESTRIA: Machine Learning Artificial Intelligence Early Detection Stroke Atrial Fibrillation UNIVERSITAETSKLINIKUM ESSEN participó en un H2020: H2020-SC1-BHC-2018-2020 Atrial fibrillation (AF) and stroke are major health care problems in Europe. They are most often the clinical expression of atrial cardiomy...
2021-01-21 - 2026-02-28 | Financiado

NECTAR: NEutron Capture enhanced Treatment of neurotoxic Amyloid aggRegates UNIVERSITAETSKLINIKUM ESSEN participó en un H2020: H2020-FETOPEN-2018-2020 NECTAR proposes an alternative and revolutionary strategy to address AD (Alzheimer’s Disease) treatment, suggesting and investigating a ther...
2021-01-20 - 2024-09-30 | Financiado

PREMSTEM: Brain injury in the premature born infant stem cell regeneration research network UNIVERSITAETSKLINIKUM ESSEN participó en un H2020: H2020-SC1-BHC-2018-2020 This project will provide new knowledge regarding the best regimen, timing, dose, and route of administration of human mesenchymal stem cell...
2019-12-06 - 2025-12-31 | Financiado

4-IN THE LUNG RUN: 4 IN THE LUNG RUN towards INdividually tailored INvitations screening INtervals and INtegrated co... UNIVERSITAETSKLINIKUM ESSEN participó en un H2020: H2020-SC1-BHC-2018-2020 With 338,000 EU-deaths annually, lung cancer is a devastating problem. CT screening has the potential to prevent ten-thousands of lung cance...
2019-12-06 - 2024-12-31 | Financiado

AutoCRAT: Automated Cellular Robot Assisted Technologies for translation of discovery led research in Osteoart... UNIVERSITAETSKLINIKUM ESSEN participó en un H2020: H2020-SC1-BHC-2018-2020 AutoCRAT will develop novel sustainable cell and cell-derived therapies for osteoarthritis (OA). Osteoarthritis, a major disease, results in...
2019-12-02 - 2024-06-30 | Financiado

THERADNET: International NETwork for training and innovations in THErapeutic RADiation UNIVERSITAETSKLINIKUM ESSEN participó en un H2020: H2020-MSCA-ITN-2019 Radiotherapy alone or in multimodality approaches is applied in 45-60% of all cancer patients, but despite technical innovations approximate...
2019-08-09 - 2023-12-31 | Financiado

UKESSEN